<DOC>
	<DOCNO>NCT02039115</DOCNO>
	<brief_summary>Complete endoscopic resection early neoplastic BE curative procedure . However , significant proportion patient develop symptomatic esophageal stricture follow CBE , limit technique , particularly circumferential longer segment disease . Oral steroid therapy may reduce stricture formation ; thereby allow CBE perform minimal associate morbidity .</brief_summary>
	<brief_title>Reduction Symptomatic Esophageal Stricture Formation</brief_title>
	<detailed_description>The main objective propose randomize trial compare rate symptomatic oesophageal strictures patient receive placebo versus oral prednisone .</detailed_description>
	<mesh_term>Constriction , Pathologic</mesh_term>
	<mesh_term>Esophageal Stenosis</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>1 . Histologically confirm Barretts mucosa high grade dysplasia early esophageal adenocarcinoma ( T1a , intramucosal adenocarcinoma ) . 2 . Barretts segment ≥ 30 % circumference , ≤C3 ≤M5 . 3 . The general health condition patient permit anesthesia endoscopy . 4 . Patient 18 year age old . 5 . Informed consent obtain 1 . Previous ( referral ) biopsies show low grade dysplasia , invasive adenocarcinoma . 2 . Barretts segment &lt; 30 % circumference , &gt; C3 &gt; M5 . 3 . During initial gastroscopy highly suspicious area submucosal invasive cancer ( Kudo pit pattern type V ; excavated/depressed type morphology ; large smooth ulcerated nodule ) . In case significant doubt , initial resection highly suspicious area , urgent histology processing request . If submucosal invasion exclude , patient rebooked 1st stage complete barrett 's excision ( 60 % circumferential resection ) randomization 46 week interval . 4 . Presence tight peptic oesophageal stricture impedes safe effective endoscopic mucosal resection use cap ( Cook Medical ) . 5 . Active malignancy , uncontrolled Diabetes Mellitus , active untreated major psychiatric disorder , uncontrolled infection , uncontrolled hypertension , uncontrolled severe congestive cardiac failure , noncorrectable coagulopathy ( INR &gt; 2 , platelet count &lt; 60 x 109/L ) , osteoporosis , recent peptic ulcer disease , moderatetosevere glaucoma untreated glaucoma , pregnancy . 6 . Unable provide inform consent 7 . Allergy compound use tablet formulation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>